Mitsubishi UFJ Trust & Banking Corp lifted its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 15.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 128,528 shares of the company's stock after purchasing an additional 17,008 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned 0.16% of DaVita worth $19,221,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the business. MML Investors Services LLC lifted its holdings in DaVita by 1.3% in the 3rd quarter. MML Investors Services LLC now owns 5,300 shares of the company's stock worth $869,000 after buying an additional 68 shares during the period. Exchange Traded Concepts LLC lifted its stake in DaVita by 8.3% in the fourth quarter. Exchange Traded Concepts LLC now owns 891 shares of the company's stock worth $133,000 after acquiring an additional 68 shares during the period. Impact Partnership Wealth LLC boosted its holdings in DaVita by 3.7% in the fourth quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company's stock valued at $290,000 after acquiring an additional 70 shares in the last quarter. Contravisory Investment Management Inc. increased its position in DaVita by 1.2% during the 4th quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company's stock valued at $910,000 after purchasing an additional 73 shares during the period. Finally, Nilsine Partners LLC raised its holdings in DaVita by 0.8% in the 4th quarter. Nilsine Partners LLC now owns 11,160 shares of the company's stock worth $1,669,000 after purchasing an additional 92 shares in the last quarter. 90.12% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on DVA shares. StockNews.com lowered shares of DaVita from a "buy" rating to a "hold" rating in a research note on Friday, March 21st. Cowen reiterated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Barclays raised their target price on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price target on DaVita in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $166.33.
Check Out Our Latest Analysis on DVA
DaVita Stock Down 0.7 %
Shares of DVA stock traded down $1.15 during trading hours on Tuesday, hitting $151.82. 718,532 shares of the company's stock traded hands, compared to its average volume of 809,341. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The stock has a market cap of $12.15 billion, a price-to-earnings ratio of 14.14, a PEG ratio of 1.07 and a beta of 0.99. The stock's fifty day simple moving average is $156.77 and its two-hundred day simple moving average is $157.44. DaVita Inc. has a 12-month low of $125.64 and a 12-month high of $179.60.
DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, analysts expect that DaVita Inc. will post 10.76 EPS for the current year.
About DaVita
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
See Also
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
